Nevirapine pharmacokinetics in HIV-infected and HIV/HCV-coinfected individuals

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 5, 2009, Pages 988-991

  Vogel, Martin ^a   Bertram, Norbert ^b   Wasmuth, Jan Christian ^a   Wyen, Christoph ^c   Voigt, Esther ^a   Schwarze Zander, Carolynne ^a   Sudhop, Thomas ^d   Fätkenheuer, Gerd ^c   Rockstroh, Jürgen K ^a   Reichel, Christoph ^a  

^a UNIVERSITY OF BONN   (Germany)

^b Laboratory for Toxicology and Analytics   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d Federal Institute for Drugs and Medical Devices   (Germany)

Author keywords

AUC; Hepatitis; Therapeutic drug monitoring

Indexed keywords

NEVIRAPINE; VIRUS RNA;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MALE; MAXIMUM PLASMA CONCENTRATION; MIXED INFECTION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; SERUM;

EID: 64649083500     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp044     Document Type: Article

References (9)

1. De Requena DG, Jimenez-Nacher I, Soriano V. Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations. AIDS Res Hum Retroviruses 2005; 21: 555-9.
2. Almond LM, Boffito M, Hoggard PG et al. The relationship between nevirapine plasma concentrations and abnormal liver function tests. AIDS Res Hum Retroviruses 2004; 20: 716-22.
3. Kappelhoff BS, van Leth F, Robinson PA et al. Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther 2005; 10: 489-98.
4. Nunez M, Gonzalez-Requena D, Gonzalez-Lahoz J et al. Short communication: Interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients. AIDS Res Hum Retroviruses 2003; 19: 187-8.
5. van Heeswijk R, Veldkamp A, Mulder J et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 2000; 14: F77-82.
6. Aranzabal L, Casado JL, Moya J et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2005; 40: 588-93.
7. Prescott LF, Newton RW, Swainson CP et al. Successful treatment of severe paracetamol overdosage with cysteamine. Lancet 1974; 1 588-92.
8. Cheng L, You Q, Yin H et al. Effect of polyI:C cotreatment on halothane-induced liver injury in mice. Hepatology 2009; 49: 215-26.
9. de Maat MM, Beijnen JH, Schellens JH et al. Chronic hepatotoxicity after long-term antiretroviral treatment including nevirapine. J Infect 2005; 50: 262-4.